Capital Flow Monitor · Sponsors · CIK 2094337
Cure Ventures Fund II, L.P.
349 NEWBURY STREET, BOSTON, MA, 02115 · 970-759-6000
Pooled Investment Fund / Venture Capital Fund · Limited Partnership· inc. DELAWARE true 2025
Fit score
—
Offering
—
Sold
$0
% sold
—
Investors
0
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | D ·current | 506(b) | — | $0 | — | 0 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- N/A Cure Ventures Fund II GP, LLC — Executive Officer, BOSTON, MA
-
David Fallace — Executive Officer, BOSTON, MA
1 other raise
- Tasca Therapeutics Corp $48.1M of $70.2M · 68.5%
- Richard Lim — Executive Officer, BOSTON, MA
- Louis Tartaglia — Executive Officer, BOSTON, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.